| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A Bayesian averted infection framework for PrEP trials with low numbers of HIV infections: application to the results of the DISCOVER trial
|
Glidden, David V
|
|
|
|
11 |
p. e791-e796
|
article
|
| 2 |
Accelerating initiation of antiretroviral therapy
|
Ford, Nathan
|
|
2016
|
|
11 |
p. e504-e505
nvt p.
|
article
|
| 3 |
A complex epidemic prevents Peru reaching HIV goals
|
Cousins, Sophie
|
|
|
|
11 |
p. e733-e734
|
article
|
| 4 |
Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report
|
Hoornenborg, Elske
|
|
2017
|
|
11 |
p. e522-e528
nvt p.
|
article
|
| 5 |
Adolescent HIV treatment in South Africa's national HIV programme: a retrospective cohort study
|
Maskew, Mhairi
|
|
|
|
11 |
p. e760-e768
|
article
|
| 6 |
AGHI: helping gay men in Nigeria
|
Adepoju, Paul
|
|
|
|
11 |
p. e738
|
article
|
| 7 |
AIDS activism through art
|
Burki, Talha
|
|
|
|
11 |
p. e749-e750
|
article
|
| 8 |
All-cause mortality among people with HIV released from an integrated system of jails and prisons in Connecticut, USA, 2007–14: a retrospective observational cohort study
|
Loeliger, Kelsey B
|
|
2018
|
|
11 |
p. e617-e628
|
article
|
| 9 |
An evolving genetic tapestry of HIV-1 recombinants
|
Paraskevis, Dimitrios
|
|
|
|
11 |
p. e733-e734
|
article
|
| 10 |
Are randomised controlled trials always required?
|
Kuhn, Louise
|
|
2015
|
|
11 |
p. e460-e461
nvt p.
|
article
|
| 11 |
Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study
|
Gandhi, Monica
|
|
2016
|
|
11 |
p. e521-e528
nvt p.
|
article
|
| 12 |
Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data
|
Yang, Xueying
|
|
|
|
11 |
p. e690-e700
|
article
|
| 13 |
Blue Diamond Society: working with Nepal's LGBT community
|
Cousins, Sophie
|
|
2018
|
|
11 |
p. e615
|
article
|
| 14 |
Bone mineral density and inflammatory and bone biomarkers after darunavir–ritonavir combined with either raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial
|
Bernardino, Jose I
|
|
2015
|
|
11 |
p. e464-e473
nvt p.
|
article
|
| 15 |
Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study
|
Hernández-Ramírez, Raúl U
|
|
2017
|
|
11 |
p. e495-e504
nvt p.
|
article
|
| 16 |
Cancer risk in people living with HIV
|
Hessol, Nancy A
|
|
2017
|
|
11 |
p. e477-e479
nvt p.
|
article
|
| 17 |
CBT for depression and drug adherence in HIV care
|
Akena, Dickens
|
|
2016
|
|
11 |
p. e503-e504
nvt p.
|
article
|
| 18 |
Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study
|
Inzaule, Seth C
|
|
2018
|
|
11 |
p. e638-e646
|
article
|
| 19 |
Cognitive behavioural therapy for adherence and depression in patients with HIV: a three-arm randomised controlled trial
|
Safren, Steven A
|
|
2016
|
|
11 |
p. e529-e538
nvt p.
|
article
|
| 20 |
Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis
|
Kanters, Steve
|
|
2016
|
|
11 |
p. e510-e520
nvt p.
|
article
|
| 21 |
Connie Norman: a warm tribute to a forgotten AIDS activist
|
Lucas, Catherine
|
|
|
|
11 |
p. e667
|
article
|
| 22 |
Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium
|
Bansi-Matharu, Loveleen
|
|
|
|
11 |
p. e711-e722
|
article
|
| 23 |
Contraceptive implants and efavirenz-based ART: friend or foe?
|
Morroni, Chelsea
|
|
2015
|
|
11 |
p. e454-e455
nvt p.
|
article
|
| 24 |
Correction
|
|
|
2017
|
|
11 |
p. e485-
1 p.
|
article
|
| 25 |
Corrections
|
|
|
2015
|
|
11 |
p. e463-
1 p.
|
article
|
| 26 |
Defining control of HIV epidemics
|
Galvani, Alison P
|
|
2018
|
|
11 |
p. e667-e670
|
article
|
| 27 |
Developing tuberculosis vaccines for people with HIV: consensus statements from an international expert panel
|
Miner, Maurine D
|
|
|
|
11 |
p. e791-e800
|
article
|
| 28 |
Disseminating complex primary outcome results from a community-randomised trial to Zambian communities: lessons learned using a community dialogue approach in the HPTN 071 (PopART) trial
|
Simwinga, Musonda
|
|
|
|
11 |
p. e801-e808
|
article
|
| 29 |
Dolutegravir drug-resistance monitoring in Africa
|
Kouamou, Vinie
|
|
|
|
11 |
p. e664-e666
|
article
|
| 30 |
Effect of UTT on viral suppression and ART adherence
|
Bachanas, Pamela
|
|
|
|
11 |
p. e738-e739
|
article
|
| 31 |
Effects of a multicomponent intervention to streamline initiation of antiretroviral therapy in Africa: a stepped-wedge cluster-randomised trial
|
Amanyire, Gideon
|
|
2016
|
|
11 |
p. e539-e548
nvt p.
|
article
|
| 32 |
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial
|
Marzinke, Mark A
|
|
|
|
11 |
p. e703-e712
|
article
|
| 33 |
Eliminating HIV in the UK among men who have sex with men
|
Trickey, Adam
|
|
|
|
11 |
p. e695-e696
|
article
|
| 34 |
Ending HIV in Chicago by 2030
|
Nelson, Roxanne
|
|
|
|
11 |
p. e702
|
article
|
| 35 |
Ethical considerations in global HIV phylogenetic research
|
Coltart, Cordelia E M
|
|
2018
|
|
11 |
p. e656-e666
|
article
|
| 36 |
Ethical issues in establishing the efficacy and safety of long-acting injectable pre-exposure prophylaxis for HIV prevention: the HPTN 083 trial
|
Sugarman, Jeremy
|
|
|
|
11 |
p. e723-e728
|
article
|
| 37 |
Financial incentives to promote retention in care and viral suppression in adults with HIV initiating antiretroviral therapy in Tanzania: a three-arm randomised controlled trial
|
Fahey, Carolyn A
|
|
|
|
11 |
p. e762-e771
|
article
|
| 38 |
First-line integrase inhibitors for HIV—prices versus benefits
|
Pozniak, Anton L
|
|
2016
|
|
11 |
p. e500-e501
nvt p.
|
article
|
| 39 |
Global and regional epidemiology of HIV-1 recombinants in 1990–2015: a systematic review and global survey
|
Hemelaar, Joris
|
|
|
|
11 |
p. e772-e781
|
article
|
| 40 |
Haematopoietic stem-cell transplantation in an HIV endemic area: time to consider donors exposed to or living with HIV
|
Hendricks, Candice Laverne
|
|
|
|
11 |
p. e742-e749
|
article
|
| 41 |
HIV and fungal priority pathogens
|
Sati, Hatim
|
|
|
|
11 |
p. e750-e754
|
article
|
| 42 |
HIV diagnosis increasing in older adults in Europe
|
Seeley, Janet
|
|
2017
|
|
11 |
p. e480-e481
nvt p.
|
article
|
| 43 |
HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis
|
Loosli, Tom
|
|
|
|
11 |
p. e733-e741
|
article
|
| 44 |
HIV elimination and population viral load
|
Okano, Justin T
|
|
2016
|
|
11 |
p. e507-e509
nvt p.
|
article
|
| 45 |
HIV funding key for sustainable development
|
The Lancet HIV,
|
|
2016
|
|
11 |
p. e499-
1 p.
|
article
|
| 46 |
HIV incidence estimation among female sex workers in South Africa: a multiple methods analysis of cross-sectional survey data
|
Kassanjee, Reshma
|
|
|
|
11 |
p. e781-e790
|
article
|
| 47 |
HIV PrEP and viral hepatitis: a unique opportunity for integration
|
Schaefer, Robin
|
|
|
|
11 |
p. e745
|
article
|
| 48 |
HIV testing and engagement with the HIV treatment cascade among men who have sex with men in Africa: a systematic review and meta-analysis
|
Stannah, James
|
|
|
|
11 |
p. e769-e787
|
article
|
| 49 |
HIV vaccine: better to start together?
|
Felber, Barbara K
|
|
|
|
11 |
p. e724-e725
|
article
|
| 50 |
Home-based oral self-testing for absent and declining individuals during a door-to-door HIV testing campaign in rural Lesotho (HOSENG): a cluster-randomised trial
|
Amstutz, Alain
|
|
|
|
11 |
p. e752-e761
|
article
|
| 51 |
Hypogonadism and bone health in men with HIV
|
Maffezzoni, Filippo
|
|
|
|
11 |
p. e782-e790
|
article
|
| 52 |
Impact of universal testing and treatment on sexual risk behaviour and herpes simplex virus type 2: a prespecified secondary outcomes analysis of the HPTN 071 (PopART) community-randomised trial
|
Wilson, Ethan
|
|
|
|
11 |
p. e760-e770
|
article
|
| 53 |
Implementation of an intensive adherence intervention in patients with second-line antiretroviral therapy failure in four west African countries with little access to genotypic resistance testing: a prospective cohort study
|
Eholie, Serge P
|
|
|
|
11 |
p. e750-e759
|
article
|
| 54 |
Incidence of first and second primary cancers diagnosed among people with HIV, 1985–2013: a population-based, registry linkage study
|
Hessol, Nancy A
|
|
2018
|
|
11 |
p. e647-e655
|
article
|
| 55 |
Incidence of virological failure and major regimen change of initial combination antiretroviral therapy in the Latin America and the Caribbean: an observational cohort study
|
Cesar, Carina
|
|
2015
|
|
11 |
p. e492-e500
nvt p.
|
article
|
| 56 |
In-depth knowledge to guide services for female sex workers
|
Viljoen, Lario
|
|
|
|
11 |
p. e739-e740
|
article
|
| 57 |
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study
|
Orkin, Chloe
|
|
|
|
11 |
p. e668-e678
|
article
|
| 58 |
Insights into HIV treatment in Latin America and the Caribbean
|
Castro, José Luis
|
|
2015
|
|
11 |
p. e458-e459
nvt p.
|
article
|
| 59 |
INSTI era resistance: emerging concern or marginal issue?
|
Kantor, Rami
|
|
|
|
11 |
p. e696-e698
|
article
|
| 60 |
Integrase strand-transfer inhibitor use and cardiovascular events in adults with HIV: an emulation of target trials in the HIV-CAUSAL Collaboration and the Antiretroviral Therapy Cohort Collaboration
|
Rein, Sophia M
|
|
|
|
11 |
p. e723-e732
|
article
|
| 61 |
Join us at The Lancet Clinic
|
Kleinert, Sabine
|
|
2015
|
|
11 |
p. e462-
1 p.
|
article
|
| 62 |
La Casa trans Zuleymi—a safe space for trans women
|
Cousins, Sophie
|
|
|
|
11 |
p. e735
|
article
|
| 63 |
Lessons from HIV deaths after incarceration
|
Spaulding, Anne C
|
|
2018
|
|
11 |
p. e606-e607
|
article
|
| 64 |
Lessons from the HPTN 071 (PopART) trial
|
Hayes, Richard
|
|
|
|
11 |
p. e736-e737
|
article
|
| 65 |
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
|
Jaeger, Hans
|
|
|
|
11 |
p. e679-e689
|
article
|
| 66 |
Male partner recruitment in Malawi's option B+ programme
|
Wall, Kristin
|
|
2015
|
|
11 |
p. e456-e457
nvt p.
|
article
|
| 67 |
Men and the young are key to reaching the first 90
|
Porter, Kholoud
|
|
2017
|
|
11 |
p. e479-e480
nvt p.
|
article
|
| 68 |
Men who have sex with men: a key population in Africa
|
Bigna, Jean Joel
|
|
|
|
11 |
p. e728-e729
|
article
|
| 69 |
Microelimination could be a big deal for HCV and HIV services
|
The Lancet HIV,
|
|
2018
|
|
11 |
p. e605
|
article
|
| 70 |
Monkeypox vaccination—an opportunity for HIV prevention
|
Mussini, Cristina
|
|
|
|
11 |
p. e741-e742
|
article
|
| 71 |
More evidence for worse COVID-19 outcomes in people with HIV
|
Boffito, Marta
|
|
|
|
11 |
p. e661-e662
|
article
|
| 72 |
Mosaic effectiveness: measuring the impact of novel PrEP methods
|
Glidden, David V
|
|
|
|
11 |
p. e800-e806
|
article
|
| 73 |
New HIV diagnoses among adults aged 50 years or older in 31 European countries, 2004–15: an analysis of surveillance data
|
Tavoschi, Lara
|
|
2017
|
|
11 |
p. e514-e521
nvt p.
|
article
|
| 74 |
New PrEP formulation approved…but only for some
|
The Lancet HIV,
|
|
|
|
11 |
p. e723
|
article
|
| 75 |
Nigeria aligns efforts for HIV epidemic control by 2030
|
Adepoju, Paul
|
|
|
|
11 |
p. e736-e737
|
article
|
| 76 |
No place like home
|
Bianchi, Andrew
|
|
|
|
11 |
p. e736
|
article
|
| 77 |
No time to defer commitment to the Global Fund
|
The Lancet HIV,
|
|
|
|
11 |
p. e735
|
article
|
| 78 |
NtRTI sparing in patients at risk of bone disease
|
Orkin, Chloe
|
|
2015
|
|
11 |
p. e452-e453
nvt p.
|
article
|
| 79 |
Opportunities and challenges for HIV self-testing in China
|
Tang, Weiming
|
|
2018
|
|
11 |
p. e611-e612
|
article
|
| 80 |
Optimising oral PrEP while awaiting long-acting cabotegravir
|
McCormack, Sheena
|
|
|
|
11 |
p. e694-e695
|
article
|
| 81 |
Optimising the accuracy of HIV drug resistance assays
|
Karim, Salim S Abdool
|
|
2018
|
|
11 |
p. e608-e609
|
article
|
| 82 |
Policy and accountability in global HIV responses
|
The Lancet HIV,
|
|
|
|
11 |
p. e731
|
article
|
| 83 |
Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study
|
Grulich, Andrew E
|
|
2018
|
|
11 |
p. e629-e637
|
article
|
| 84 |
Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline
|
Coelho, Lara Esteves
|
|
|
|
11 |
p. e788-e799
|
article
|
| 85 |
Pregnancy rates in HIV-positive women using contraceptives and efavirenz-based or nevirapine-based antiretroviral therapy in Kenya: a retrospective cohort study
|
Patel, Rena C
|
|
2015
|
|
11 |
p. e474-e482
nvt p.
|
article
|
| 86 |
PrEP and the PrEPstars
|
Morgan, Jules
|
|
2018
|
|
11 |
p. e616
|
article
|
| 87 |
PrEP for African migrants in Europe? A research agenda
|
Loos, Jasna
|
|
2016
|
|
11 |
p. e505-e507
nvt p.
|
article
|
| 88 |
PrEP retention and prescriptions for pregnant women during COVID-19 lockdown in South Africa
|
Davey, Dvora L Joseph
|
|
|
|
11 |
p. e735
|
article
|
| 89 |
Prioritise people with HIV for COVID-19 vaccination
|
HIV, The Lancet
|
|
|
|
11 |
p. e659
|
article
|
| 90 |
Progress of UNAIDS 90-90-90 targets in a district in KwaZulu-Natal, South Africa, with high HIV burden, in the HIPSS study: a household-based complex multilevel community survey
|
Grobler, Anneke
|
|
2017
|
|
11 |
p. e505-e513
nvt p.
|
article
|
| 91 |
Projected outcomes of universal testing and treatment in a generalised HIV epidemic in Zambia and South Africa (the HPTN 071 [PopART] trial): a modelling study
|
Probert, William J M
|
|
|
|
11 |
p. e771-e780
|
article
|
| 92 |
Raltegravir becomes a once daily antiretroviral
|
Raffi, François
|
|
2017
|
|
11 |
p. e476-e477
nvt p.
|
article
|
| 93 |
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial
|
Cahn, Pedro
|
|
2017
|
|
11 |
p. e486-e494
nvt p.
|
article
|
| 94 |
Rapidly declining HIV infection in MSM in central London
|
Nwokolo, Nneka
|
|
2017
|
|
11 |
p. e482-e483
nvt p.
|
article
|
| 95 |
Reaching Nepal's mobile population at risk of HIV
|
Cousins, Sophie
|
|
2018
|
|
11 |
p. e613-e614
|
article
|
| 96 |
Reassessing oral lead-in for injectable long-acting HIV therapy
|
Llibre, Josep M
|
|
|
|
11 |
p. e660-e661
|
article
|
| 97 |
Recruiting male partners for couple HIV testing and counselling in Malawi's option B+ programme: an unblinded randomised controlled trial
|
Rosenberg, Nora E
|
|
2015
|
|
11 |
p. e483-e491
nvt p.
|
article
|
| 98 |
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study
|
Lataillade, Max
|
|
|
|
11 |
p. e740-e751
|
article
|
| 99 |
Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial
|
Pantaleo, Giuseppe
|
|
|
|
11 |
p. e737-e749
|
article
|
| 100 |
Safety data needed for concurrent use of ARV-based PrEP
|
Dunbar, Megan S
|
|
|
|
11 |
p. e742-e744
|
article
|
| 101 |
Secondary distribution of HIV self-tests improves coverage
|
Sibanda, Euphemia L
|
|
|
|
11 |
p. e732-e733
|
article
|
| 102 |
Second primary cancer in people with HIV
|
Franceschi, Silvia
|
|
2018
|
|
11 |
p. e610-e611
|
article
|
| 103 |
Silver bullets and structural impediments to HIV prevention
|
Mayer, Kenneth H
|
|
|
|
11 |
p. e729-e732
|
article
|
| 104 |
Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study
|
Nomah, Daniel K
|
|
|
|
11 |
p. e701-e710
|
article
|
| 105 |
Successes and challenges in Thailand's HIV response
|
Barmania, Sima
|
|
|
|
11 |
p. e699-e700
|
article
|
| 106 |
Suicide prevention research is crucial to achieving health equity for people with HIV
|
Liu, Yuming
|
|
|
|
11 |
p. e745-e746
|
article
|
| 107 |
Taking the long-view in a personalised approach to HIV care
|
Lazarus, Jeffrey V
|
|
2017
|
|
11 |
p. e483-e485
nvt p.
|
article
|
| 108 |
Tangerine Clinic: championing transgender health care
|
Barmania, Sima
|
|
|
|
11 |
p. e701
|
article
|
| 109 |
Testing times
|
The Lancet HIV,
|
|
2015
|
|
11 |
p. e451-
1 p.
|
article
|
| 110 |
The benefits and risks of PrEP and kidney function
|
Mocroft, Amanda
|
|
2016
|
|
11 |
p. e501-e502
nvt p.
|
article
|
| 111 |
The drugs crisis and AIDS in 1980s Edinburgh
|
Burki, Talha
|
|
|
|
11 |
p. e739
|
article
|
| 112 |
The effect of combination prevention strategies on HIV incidence among gay and bisexual men who have sex with men in the UK: a model-based analysis
|
Cambiano, Valentina
|
|
|
|
11 |
p. e713-e722
|
article
|
| 113 |
Time to strengthen HIV treatment and prevention for youth
|
Pettifor, Audrey
|
|
|
|
11 |
p. e727-e728
|
article
|
| 114 |
Transition to third-line ART in resource-limited settings
|
Cohen, Karen
|
|
|
|
11 |
p. e725-e727
|
article
|
| 115 |
Transplant donation without discrimination
|
The Lancet HIV,
|
|
|
|
11 |
p. e693
|
article
|
| 116 |
Ukraine adapts its HIV response
|
Holt, Ed
|
|
|
|
11 |
p. e747-e748
|
article
|
| 117 |
U=U taking off in 2017
|
The Lancet HIV,
|
|
2017
|
|
11 |
p. e475-
1 p.
|
article
|
| 118 |
Viral suppression and self-reported ART adherence after 3 years of universal testing and treatment in the HPTN 071 (PopART) community-randomised trial in Zambia and South Africa: a cross-sectional analysis
|
Macleod, David
|
|
|
|
11 |
p. e751-e759
|
article
|
| 119 |
Weight and antiretrovirals: a new episode in a long series
|
Capeau, Jacqueline
|
|
|
|
11 |
p. e663-e664
|
article
|
| 120 |
What happens when PrEP is scaled up? Results from EPIC-NSW
|
McCormack, Sheena
|
|
2018
|
|
11 |
p. e607-e608
|
article
|
Journal description